drugset / Trial / NCT00463021

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

NCT00463021

Phase 4 Completed 36 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupOpen-labelTreatment

Summary

Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.

Timeline

Start
2007-04
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxercalciferol Small molecule
Background Paricalcitol Other / unclassified